Acquired Company
Gelesis, Inc. completed its business combination with Capstar Special Purpose Acquisition Corp. on January 13, 2022, after which CPSR changed its name to Gelesis Holdings, Inc. and the combined company began trading on NYSE under GLS.
Gelesis is a consumer-centered biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Its non-systemic superabsorbent hydrogels are the first and only made entirely from naturally derived building blocks, and they are inspired by the composition (i.e., water & cellulose) and mechanical properties (e.g., elasticity or firmness) of raw vegetables. They are conveniently administered in capsules to create a much larger volume of small, non-aggregating hydrogel pieces that become an integrated part of the meals, and act locally in the digestive system. Its portfolio includes Plenity®, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation. Show more
Location: 501 Boylston Street, Suite 6102, MA, 02116, US | Website: www.gelesis.com | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services
Market Cap
0.00
52 Wk Range
$N/A - $N/A
Previous Close
$0.16
Open
$N/A
Volume
N/A
Day Range
$N/A - $N/A
Enterprise Value
0.00
Cash
0.00
Avg Qtr Burn
N/A
Insider Ownership
52.70%
Institutional Own.
29.38%
Qtr Updated
06/30/24
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Plenity Details Obesity | Approved Quarterly sales | |
Plenity Details Obesity | Failed Discontinued | |
GS200 Details Obesity, Diabetes, Type 2 diabetes | Failed Discontinued |
